CD34 and acute myeloid leukemia: Furthermore, bortezomib resulted in a reduction in the proportion of human LSC (characterized by CD34+ CD38‐ phenotype) and increased the general survival in mice engrafted with AML blasts, particularly in the NOD/SCID‐IL2Rγ (NSG) model [62].